



ASH 2017 Day Three Update Atlanta, GA

Dr. Brian Koffman – Hi. Dr. Brian Koffman here at the third and long and exhausting day at ASH 2017 in Atlanta, GA... and a lot of exciting new stuff to share. Had some amazing interviews with new information on CLL that I'll be sharing with you over the next few weeks.

I attended the oral sessions where some of the most important research was presented. Learned things about opportunist infections in CLL. What are the risk factors for those? Monoclonal B Cell Lymphocytosis or MBL, which is a precursor to CLL. And the problems and complications that are associated with that, which really hasn't been well studied.

We learned about some of the early literature on ROR1, Cirmtuzumab, an antibody that attacks ROR1 in its early applicancy in early trials in CLL.

And much more, after that.

There were the poster sessions that covered multiple topics in CLL, including looking at drug combinations and preclinical data in terms of what might be helpful.

So, I look forward to presenting this all to you over the next few weeks and I look forward to getting a good night's sleep tonight.

Thanks, Dr. Brian Koffman.